PharmacoEconomics & Outcomes News 792, p33 - 2 Dec 2017
NICE invites Merck to submit CDF
proposal for skin cancer drug
NICE has asked Merck to submit a Cancer Drugs Fund
(CDF) proposal for their immunotherapy drug,
meaning patients with Merckel
cell carcinoma will be able to access the drug while the
company gathers more evidence for future
resubmission to the NICE committee.
NICE’s initial assessment showed that avelumab can
extend patient survival compared with chemotherapy
according to current clinical data; however, this
evidence comes from one small trial and data is still
being collected, so further evidence is needed to
confirm these findings.
Commenting on the announcement, Director of the
Centre for Health Technology Evaluation at NICE,
Professor Carole Longson, said "Merkel cell carcinoma is
a rare and aggressive form of cancer. There are limited
treatment options and the cancer can spread rapidly,
which we know can be frightening for both patients and
families . . . Avelumab is a promising treatment that has
the potential to be cost effective. I hope Merck will work
with us to submit a CDF proposal".
NICE. Merck invited to submit a CDF proposal for Merkel cell cancer drug.
Internet Document : 27 Nov 2017. Available from: URL: https://www.nice.org.uk/
PharmacoEconomics & Outcomes News 2 Dec 2017 No. 7921173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved